Dyslipidaemia in nephrotic syndrome: mechanisms and treatment

@article{Agrawal2018DyslipidaemiaIN,
  title={Dyslipidaemia in nephrotic syndrome: mechanisms and treatment},
  author={Shipra Agrawal and Joshua Jacob Zaritsky and Alessia Fornoni and William E. Smoyer},
  journal={Nature Reviews Nephrology},
  year={2018},
  volume={14},
  pages={57-70}
}
Nephrotic syndrome is a highly prevalent disease that is associated with high morbidity despite notable advances in its treatment. Many of the complications of nephrotic syndrome, including the increased risk of atherosclerosis and thromboembolism, can be linked to dysregulated lipid metabolism and dyslipidaemia. These abnormalities include elevated plasma levels of cholesterol, triglycerides and the apolipoprotein B-containing lipoproteins VLDL and IDL; decreased lipoprotein lipase activity in… CONTINUE READING
2 Citations
152 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.
Showing 1-10 of 152 references

REVEAL: CETP inhibitor anacetrapib meets primary end point

  • M. Brooks
  • Medscape Nephrology
  • 2017

Similar Papers

Loading similar papers…